Tech Company Financing Transactions

Audentes Therapeutics Funding Round

Redmile Group, Sofinnova Ventures and 5AM Ventures joined a $65 million Series C funding round for Audentes Therapeutics. The financing round closed on 10/14/2015.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

600 California St. 17th Floor
San Francisco, CA 94108
USA

Phone

(415) 818-1001

Website

www.audentestx.com

Email Address

[email protected]

Overview

Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Matthew Patterson

        

Chief Financial Officer

Thomas Soloway

        

Chief Operating Officer

Natalie Holles

        

Vice President

Fulvio Mavilio

        

VP - Regulatory Affairs

Mary Newman

        

Browse more venture capital transactions:

Prev: 10/14/2015: Doctolib venture capital transaction
Next: 10/14/2015: DataVisor venture capital transaction

Share this article

News on VC Transactions

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary